| Literature DB >> 28779413 |
Yusuke Koizumi1,2, Takuro Sakagami3, Naoya Nishiyama4,5, Jun Hirai4,5, Yuta Hayashi6, Nobuhiro Asai4,5, Yuka Yamagishi4,5, Hideo Kato5, Mao Hagihara5, Daisuke Sakanashi5, Hiroyuki Suematsu5, Kenji Ogawa6, Hiroshige Mikamo4,5.
Abstract
A 67-year-old Japanese female with back pain and severe cachexia visited our hospital. The diagnosis was disseminated Mycobacterium avium complex infection (dMAC) with multiple bone involvement. Anti-mycobacterial chemotherapy was started, but fever persisted and dislocation of cervical vertebrae has made her bedridden. Because anti-interferon (IFN)-γ autoantibody was positive, four doses of rituximab 375 mg/m2, every 7 day, were administered. Soon after treatment, progression of osteolytic lesions and wasting has stopped. We proved that rituximab has recovered IFN-γ signaling as shown by IFN-γ-induced STAT1 phosphorylation. It can be a promising option for dMAC cases with anti-IFN-γ autoantibody.Entities:
Keywords: Disseminated Mycobacterium avium complex infection; anti-interferon-γ autoantibody; bone involvement; rituximab; signal transducer and activator of transcription (STAT)1
Mesh：
Substances：
Year: 2017 PMID： 28779413 DOI： 10.1007/s10875-017-0425-3
Source DB: PubMed Journal: J Clin Immunol ISSN： 0271-9142 Impact factor: 8.317